Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 20/20 | 0.63 |
| ▸ | LGALS1 | P09382 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22247087 | 1.00 | LGALS3 (0.63) | LGALS3LGALS1 | |
| SCHEMBL22247211 | 0.94 | LGALS3 (0.58) | LGALS3LGALS1 | |
| SCHEMBL22247287 | 0.94 | LGALS3 (0.59) | LGALS3LGALS1 | |
| SCHEMBL22247276 | 0.93 | LGALS3 (0.63) | LGALS3 | |
| SCHEMBL22247210 | 0.93 | LGALS3 (0.60) | LGALS3LGALS1 | |
| SCHEMBL22247157 | 0.93 | LGALS3 (0.59) | LGALS3LGALS1 | |
| SCHEMBL22247202 | 0.92 | LGALS3 (0.59) | LGALS3LGALS1 | |
| SCHEMBL22247165 | 0.92 | LGALS3 (0.56) | LGALS3LGALS1 | |
| SCHEMBL22247167 | 0.92 | LGALS3 (0.60) | LGALS3LGALS1 | |
| SCHEMBL22247160 | 0.92 | LGALS3 (0.57) | LGALS3LGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | GLYCOMIMETICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2020150263-A1 | SELECTIN OR GALECTIN ANTAGONISTS FOR TREATING CYTOKINE RELEASE SYNDROME AND CRS-INDUCED NEUROTOXICITY | MAGNANI JOHN L (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | LGALS3, LGALS3BP, LGALS1 | LGALS3 1/4885LGALS1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.